Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Enanta Pharmaceuticals Inc
ENTA | US
12.64
USD0.01
0.08%
ENTA | US
About Enanta Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
12.64
Open
12.59
High
12.88
Low
12.40
Enanta Pharmaceuticals Inc. a biotechnology company discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus SARS-CoV-2 human metapneumovirus and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify develop and commercialize HCV NS3 and NS3/4A protease inhibitor compounds including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals Inc. was founded in 1995 and is headquartered in Watertown Massachusetts.
View LessENTA | US
Risk
46.2
Sharpe
0.37
Luna's Score
43/100
Recommendation
Sell
Luna says (ENTA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
43.8%1 month
46.2%3 months
52.7%6 months
54.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.80
Debt to equity
1.52
Debt to assets
0.57
Ent. to EBITDA
-0.29
Ent. to rev.
1.22
PEG
-
Other Fundamentals
EBITDA
-120.34M
MarketCap
267.82M
MarketCap(USD)
267.82M
Div. yield
-
Op. margin
-134.58
Erngs. growth
-66.20
Rev. growth
-4.90
Ret. on equity
-59.64
Short ratio
17.23
Short perc.
14.98
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
2.48
Range1M
2.99
Range3M
6.03
Volumes: Market Activity
Rel. volume
0.86
Price X volume
2.05M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.29 | - | Cheaper |
| Ent. to Revenue | 1.22 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.80 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 52.74 | - | Lower Risk |
| Debt to Equity | 1.52 | -1.23 | Expensive |
| Debt to Assets | 0.57 | 0.25 | Expensive |
| Market Cap | 267.82M | - | Emerging |
